Risk of clinically significant depression in HIV‐infected patients: effect of antiretroviral drugs
Authors:
Open Access
- 11 November 2013
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 15 (4) , 213-223
Abstract
Objectives: We aimed to characterize depression in newly diagnosed HIV‐infected patients, to determine the effect of antiretroviral therapy (ART) on its incidence, and to investigate whether efavirenz use was associated with a higher risk, compared with non‐efavirenz‐containing regimens, in the Spanish CoRIS cohort.Methods: CoRIS is a contemporary, multicentre cohort of HIV‐infected patients, antiretroviral‐naïve at entry, launched in 2004. Poisson regression models were used to investigate demographic, clinical and treatment‐related factors associated with a higher incidence of clinically significant depression to October 2010.Results: In total, 5185 patients (13 089 person‐years) participated in the study, of whom 3379 (65.2%) started ART during follow‐up. The incidence rates of depression before and after starting ART were 11.68 [95% confidence interval (CI) 9.01–15.15] and 7.06 (95% CI 5.45–9.13) cases per 1000 person‐years, respectively. After adjustment, there was an inverse association between the occurrence of depression and the initiation of ART [incidence rate ratio (IRR) 0.53; 95% CI 0.28–0.99], while the likelihood of depression increased in patients of age > 50 years (IRR 1.94; 95% CI 1.21–3.12). Longer exposure to ART was associated with a decreased IRR of depression in unadjusted and adjusted analyses. The IRR for patients receiving < 2, 2–4 and > 4 years of ART was 0.72 (95% CI 0.36–1.44), 0.10 (95% CI 0.04–0.25) and 0.05 (95% CI 0.01–0.17), respectively, compared with ART‐naïve patients. This protective effect was also observed when durations of exposure to nonnucleoside reverse transcriptase inhibitor‐based regimens and efavirenz‐containing regimens were analysed separately.Conclusions: The incidence of clinically significant depression was lower among HIV‐infected patients on ART. The protective effect of ART was also observed with efavirenz‐containing regimens.Keywords
Funding Information
- Red Tem�tica de Investigaci�n Cooperativa en VIH/SIDA-ISC III-RETIC, and Instituto de Salud Carlos III-FIS, Spanish Ministry of Health (RD06/0027-RD12/0017-PI081893)
This publication has 34 references indexed in Scilit:
- Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patientsAIDS, 2013
- Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: A possible mechanism for AIDS comorbid depressionBrain, Behavior, and Immunity, 2011
- Inflammation-associated depression: From serotonin to kynureninePsychoneuroendocrinology, 2011
- Central Administration of Lipopolysaccharide Induces Depressive-like Behavior in Vivo and Activates Brain Indoleamine 2,3 Dioxygenase In Murine Organotypic Hippocampal Slice CulturesJournal of Neuroinflammation, 2010
- Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)HIV Research & Clinical Practice, 2009
- Induction of IDO by Bacille Calmette-Guérin Is Responsible for Development of Murine Depressive-Like BehaviorThe Journal of Immunology, 2009
- Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in miceMolecular Psychiatry, 2008
- From inflammation to sickness and depression: when the immune system subjugates the brainNature Reviews Neuroscience, 2008
- The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAARTAIDS, 2007
- Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099Clinical Infectious Diseases, 2006